SCHEDULE: 5AM Ventures Adjusts Skye Bioscience Stake

This Schedule 13D filing details amendments to beneficial ownership by 5AM Ventures entities and individuals, reflecting recent share transactions and a 1-for-8 reverse stock split.

Summary

• This filing is an amendment to a Schedule 13D, reporting changes in beneficial ownership of Skye Bioscience, Inc. common stock by several 5AM Ventures entities and individuals.
• The reporting persons have collectively adjusted their holdings, with significant open market and block sales occurring in August and September 2026.
• The share numbers reflect a 1-for-8 reverse stock split that occurred on August 24, 2026.
• As of the filing date, 5AM Ventures VII, L.P. and 5AM Partners VII, LLC hold 1,194,443 shares, representing 25.7% of the outstanding common stock.
• Andrew J. Schwab holds an aggregate of 1,218,088 shares, representing 26.1% of the outstanding common stock, including shares from stock options.
• Several transactions involving sales of shares by 5AM Ventures entities are detailed, occurring between August 19, 2026, and September 23, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant share sales and a decrease in beneficial ownership percentage, indicating a potential lack of confidence or strategic shift by major holders.

Positives

• The filing provides clear disclosure of beneficial ownership changes, adhering to regulatory requirements.
• The reverse stock split is noted, which can sometimes be a precursor to strategic corporate actions or uplisting efforts.

Negatives

• Significant open market and block sales by reporting persons indicate a reduction in their stake in Skye Bioscience.
• The aggregate beneficial ownership percentage has decreased for some reporting entities.
• The filing details multiple sales transactions, suggesting a divestment strategy by these entities.

Risks

• The substantial sales by major holders could signal a lack of confidence in the company's near-term prospects, potentially impacting share price.
• Future sales by these entities could continue to exert downward pressure on the stock price.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company itself, but rather details changes in beneficial ownership and past transactions.

Industry Context

StockSavvy.ai notes that venture capital firms frequently adjust their holdings in portfolio companies, especially after significant corporate actions like reverse splits or during periods of market volatility. The sales detailed here are typical for VC fund lifecycle management, though the scale can be indicative of sentiment.

Stakeholder Impact

• Shareholders may be concerned by the significant sales from major holders, potentially leading to increased stock price volatility or downward pressure.
• Potential investors may view the sales as a negative signal regarding the company's future performance.

Next Steps

• Continued monitoring of 5AM Ventures' beneficial ownership and any further transactions.
• Observation of Skye Bioscience, Inc.'s performance and strategic developments following the reverse split and reported share sales.

Key Dates

Recommendation

While the significant sales by 5AM Ventures are a negative signal, the filing itself is primarily a disclosure of ownership changes and past transactions. Without new operational or financial information from Skye Bioscience, a 'hold' recommendation is prudent, pending further developments or clarity on the reasons behind the sales.

Keywords

Skye Bioscience, Schedule 13D, Beneficial Ownership, 5AM Ventures, Stock Sale, Reverse Split, Venture Capital